CHEK2 mutations and the risk of papillary thyroid cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|3|548-552

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.3, 2015-08, pp. : 548-552

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Outcomes of Papillary Thyroid Cancer Patients in Different Risk Groups

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 123-129

Karger

Access to resources Recommend Favorite

Age at Onset of Bilateral Breast Cancer, the Presence of Hereditary BRCA1, BRCA2, CHEK2 Gene Mutations and Positive Family History of Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 4, 2009-03 ,pp. : 182-188

Karger

Access to resources Recommend Favorite

TROP‐2 expression in papillary thyroid cancer: a preliminary cyto‐histological study

By  

CYTOPATHOLOGY, Vol. 956-5507, Iss. 5, 2015-10 ,pp. : 303-311

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness analysis of papillary thyroid cancer surveillance

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4132-4140

John Wiley & Sons Inc

Access to resources Recommend Favorite

Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 10, 2015-10 ,pp. : 593-602

John Wiley & Sons Inc

Access to resources Recommend Favorite